a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

MRI of inhaled perfluoropropane can assess regional lung ventilation and monitor improvements in response to medication ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

For individuals with chronic lung conditions, the winter season and the current cold snap poses significant challenges. We ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

New Study Shows Promising Results for COPD Treatment Nov. 20 ... molecule is as sneaky as its inventors ... COPD and BPD: Inhalation of Live Lactobacilli Lessens Lung Inflammation and Improves ...

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

Oxygen is essential to life. The respiratory system works tirelessly to provide fresh oxygen to the body and ensure that all ...